Title |
Safety of Daily Co-Trimoxazole in Pregnancy in an Area of Changing Malaria Epidemiology: A Phase 3b Randomized Controlled Clinical Trial
|
---|---|
Published in |
PLOS ONE, May 2014
|
DOI | 10.1371/journal.pone.0096017 |
Pubmed ID | |
Authors |
Christine Manyando, Eric M. Njunju, David Mwakazanga, Gershom Chongwe, Rhoda Mkandawire, Davies Champo, Modest Mulenga, Maaike De Crop, Yves Claeys, Raffaella M. Ravinetto, Chantal van Overmeir, Umberto Dā Alessandro, Jean-Pierre Van geertruyden |
Abstract |
Antibiotic therapy during pregnancy may be beneficial and impacts positively on the reduction of adverse pregnancy outcomes. No studies have been done so far on the effects of daily Co-trimoxazole (CTX) prophylaxis on birth outcomes. A phase 3b randomized trial was conducted to establish that daily CTX in pregnancy is not inferior to SP intermittent preventive treatment (IPT) in reducing placental malaria; preventing peripheral parasitaemia; preventing perinatal mortality and also improving birth weight. To establish its safety on the offspring by measuring the gestational age and birth weight at delivery, and compare the safety and efficacy profile of CTX to that of SP. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
Ghana | 1 | <1% |
Ethiopia | 1 | <1% |
Australia | 1 | <1% |
Peru | 1 | <1% |
Unknown | 175 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 33 | 18% |
Researcher | 23 | 13% |
Student > Ph. D. Student | 19 | 10% |
Student > Doctoral Student | 11 | 6% |
Other | 8 | 4% |
Other | 35 | 19% |
Unknown | 52 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 61 | 34% |
Nursing and Health Professions | 17 | 9% |
Agricultural and Biological Sciences | 11 | 6% |
Biochemistry, Genetics and Molecular Biology | 6 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
Other | 26 | 14% |
Unknown | 54 | 30% |